GlassScriptPhysician profile
Matthew L Krauza
NPI 1740211309
$7,138.11
in general payments reported to CMS, 2019-2025
40 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $1,138 · 2021: $1,564 · 2022: $1,513 · 2023: $753 · 2024: $673 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,499.93 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $774.08 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.45 | 2019-2023 | Stiolto Respimat, Ofev, Spiriva Respimat |
| United Therapeutics Corporation | $637.01 | 2019-2025 | Tyvaso, Tyvaso |
| Inspire Medical Systems, INC. | $504.40 | 2021-2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $269.65 | 2019-2023 | Opsumit |
| Jazz Pharmaceuticals INC. | $255.47 | 2019-2024 | Xywav |
| Genzyme Corporation | $236.36 | 2020-2022 | |
| Harmony Biosciences LLC | $232.27 | 2021-2022 | |
| Mylan Specialty L.P. | $169.63 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $155.66 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.55 | 2021-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $132.95 | 2021-2022 | |
| Electromed, INC. | $131.59 | 2022-2025 | Smartvest |
| Insmed, INC. | $125.56 | 2020-2025 | Arikayce |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Krauza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.